HALB (Halberd) EV-to-EBIT: (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Halberd EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Halberd's Enterprise Value is $0.64 Mil. Halberd does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Jul. 2023. Therefore, GuruFocus does not calculate Halberd's EV-to-EBIT at this moment.

The historical rank and industry rank for Halberd's EV-to-EBIT or its related term are showing as below:

HALB' s EV-to-EBIT Range Over the Past 10 Years
Min: -1.58   Med: 0   Max: 0
Current: -1.43
HALB's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 12.165 vs HALB: -1.43

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Halberd's Enterprise Value for the quarter that ended in Jul. 2023 was $5.63 Mil. Halberd does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Jul. 2023. Therefore, GuruFocus does not calculate Halberd's Earnings Yield (Joel Greenblatt) % at this moment.

Halberd  (OTCPK:HALB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Halberd's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jul. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jul. 2023 ) =EBIT / Enterprise Value (Q: Jul. 2023 )
=/5.6329875
= %

Halberd EV-to-EBIT Related Terms

Halberd EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Halberd's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halberd EV-to-EBIT Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
EV-to-EBIT
0.00 -4.04 -12.60

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
EV-to-EBIT 0.00 -4.04 -12.60

HALB vs GRI, OCEA, PCSA: EV-to-EBIT Comparison

For the Biotechnology subindustry, Halberd's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halberd EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Halberd's EV-to-EBIT falls into.


Halberd EV-to-EBIT Calculation

Halberd's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.637/
=

Halberd Business Description

Address P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a holding company and acquisition vehicle for established businesses. It is also developing a patented process for disease eradication by removing the pathophysiologic basis of the disease. The company is focused on developing treatments for neurodegenerative diseases, such as PTSD and CTE (Post Traumatic Stress Disorder and Chronic Traumatic Encephalopathy), Alzheimer's Disease, Parkinson's Disease, etc.